Teva Pharmaceutical Industries Limited
TEVANYSE · Healthcare · Drug Manufacturers - Specialty & GenericTeva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and b…
$42.61+1.99%
报价 2026-11-06
市值
$49.65B
EV
$61.67B
PE (TTM)
93.0x
预期 PE (FY2026)
20.8x
52 周区间距高点 0.0%
$24.21$42.61
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Drug Manufacturers - Specialty & Generic| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| TEVATeva Pharmaceutical Industries Limited | $49.65B | +2.0% | -0.7% | 55.5% | 93.0x | 30.3x | 39.5x | |
| TAKTakeda Pharmaceutical Company Limited | $66.35B | -0.8% | – | 59.5% | 79.2x | 9.8x | – | |
| HLNHaleon plc | $40.19B | -0.1% | – | 61.8% | 21.8x | 14.3x | – | |
| ZTSZoetis Inc. | $32.81B | -3.3% | +3.8% | 70.5% | 18.9x | 14.2x | 14.3x | |
| VTRSViatris Inc. | $22.87B | +5.0% | +4.6% | 38.8% | – | 12.4x | 11.2x | |
| NBIXNeurocrine Biosciences, Inc. | $16.66B | +3.0% | +39.8% | 97.6% | 23.6x | 17.3x | 16.0x | 高增长 |
| ELANElanco Animal Health Incorporated | $12.86B | +8.7% | +10.1% | 56.9% | – | 23.7x | 31.5x | GARP |
| RDYDr. Reddy's Laboratories Limited | $12.42B | +2.6% | – | 55.2% | 18.5x | 12.5x | – | |
| AMRXAmneal Pharmaceuticals, Inc. | $7.01B | +3.5% | +6.2% | 42% | 41.2x | 14.1x | 78.8x | |
| 同行中位数 | – | – | +6.2% | 58.2% | 22.7x | 14.2x | 16.0x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.4B | $4.14B | $3.98B | $4.71B | $4.48B | $4.18B | $3.89B | $4.23B |
| Gross Margin | 55.5% | 52% | 49.5% | 56.4% | 51.4% | 50.3% | 48.2% | 50.1% |
| Operating Margin | 16.2% | 3.6% | 16.4% | 6.4% | 19.7% | 10.9% | 13.3% | -0.7% |
| Net Income | $233M | $-576M | $369M | $480M | $433M | $282M | $214M | $-217M |
| Diluted EPS | 0.2 | -0.49 | 0.31 | 0.41 | 0.37 | 0.24 | 0.18 | -0.19 |
| Operating Cash Flow | $241M | $411M | $-40M | $1.16B | $369M | $227M | $-105M | $575M |